BioVersys and Enamine Announce Extension of Drug Discovery Collaboration to Address Multidrug-Resistant Bacterial Infections
Advertisement
Enamine Ltd. and BioVersys AG announced the extension of their drug discovery collaboration for the 4th consecutive year. Since the start of the collaboration Enamine has provided expertise in screening of compounds and chemistry know-how for hit finding activities and optimization. BioVersys has brought its approach and knowledge of antimicrobial resistance into the partnership. The new agreement covers further involvement of Enamine’s HTS platform and ADME profiling capabilities. Enamine has expanded its team of medicinal chemists to support the collaboration.
Financial details were not disclosed. The IP generated by the collaboration is owned by BioVersys.